Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are […]